Patents by Inventor Eu Ddeum CHUNG

Eu Ddeum CHUNG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANGIOGENESIS INHIBITOR-CONJUGATED ANTI-C3B ANTIBODY OR ANTI-C5 ANTIBODY AND USE THEREOF
    Publication number: 20250074974
    Abstract: The present invention relates to a fusion protein comprising an anti-C3b antibody or an anti-C5 antibody and an angiogenesis inhibitor, and a composition for treating eye diseases, particularly macular degeneration, by using the same. The protein may not only inhibit complement-related pathways, but can also efficiently regulate angiogenesis. Therefore, the fusion protein dimer can be effectively used to treat and prevent complement-related diseases, particularly eye diseases such as macular degeneration, and thus has high industrial applicability.
    Type: Application
    Filed: December 27, 2022
    Publication date: March 6, 2025
    Inventors: Eu Ddeum Chung, Soomin Ryu, Donggeon Kim, Jihoon Chang, Byoung Chul Lee
  • SHP2 inhibitor and use thereof
    Patent number: 12029739
    Abstract: The present invention relates to an inhibitor of SHP2, a pharmaceutical composition for preventing or treating a disease related to SHP2 comprising the same, a method for treating and preventing a disease using the same, and a use thereof. Accordingly, the present invention can effectively prevent or treat diseases related to SHP2.
    Type: Grant
    Filed: January 8, 2024
    Date of Patent: July 9, 2024
    Assignee: KANAPH THERAPEUTICS INC.
    Inventors: Miyeon Kim, Dohyun Park, Dongsu Kim, Kyeongjin Yoon, Sungpil Choi, Sang Kyun Lim, Eu Ddeum Chung, Mijung Lee, Dahye Jeon, Soyeon Jang, Kyungik Lee, Jinhwan Kim, Eunji Kim, Jieun Min, Kangwoo Lee, Jakyung Yoo
  • SHP2 INHIBITOR AND USE THEREOF
    Publication number: 20240189306
    Abstract: The present invention relates to an inhibitor of SHP2, a pharmaceutical composition for preventing or treating a disease related to SHP2 comprising the same, a method for treating and preventing a disease using the same, and a use thereof. Accordingly, the present invention can effectively prevent or treat diseases related to SHP2.
    Type: Application
    Filed: January 8, 2024
    Publication date: June 13, 2024
    Inventors: Miyeon KIM, Dohyun PARK, Dongsu KIM, Kyeongjin YOON, Sungpil CHOI, Sang Kyun LIM, Eu Ddeum CHUNG, Mijung LEE, Dahye JEON, Soyeon JANG, Kyungik LEE, Jinhwan KIM, Eunji KIM, Jieun MIN, Kangwoo LEE, Jakyung YOO
  • FUSION PROTEIN INCLUDING COMPLEMENT PATHWAY INHIBITOR AND ANGIOGENESIS INHIBITOR AND USE THEREOF
    Publication number: 20230242633
    Abstract: Provided is a fusion protein dimer containing an extracellular domain of CRIg or a fragment thereof, and a protein that specifically binds to VEGF. The protein may not only inhibit complement-related pathways, but also effectively modulate angiogenesis. Therefore, the fusion protein dimer may be effectively used for the treatment and prevention of complement-related diseases, specifically, eye diseases such as macular degeneration, and thus a high possibility of being industrially used.
    Type: Application
    Filed: July 7, 2021
    Publication date: August 3, 2023
    Inventors: Eu Ddeum CHUNG, Soomin RYU, Donggeon KIM, Jihoon CHANG, Byoung Chul LEE